Lundbeckfonden Ventures News

Lund, Sweden, 08.00 CET, 14 November 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, announces the publication of a paper highlighting the anti-biofilm activity of CERAMENT® G in vitro – Colloids and Surfaces B:...
November 1, 2017 CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00...
Lund, Sweden, 08.00 CET, 2 November 2017 – BONESUPPORT™, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces the publication of its Interim Report January – September 2017. Q3 Net sales increased by 23% FINANCIAL HIGHLIGHTS...
Lund, Sweden, 18:00 CET 31st October 2017 – During October, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 31st October 2017, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 49,900,591. For more information contact: Richard Davies, CEO Tel:...
EB8018 is an oral small molecule targeting the host-microbiome interaction by blocking FimH   PARIS and CAMBRIDGE, Massachusetts, October 27, 2017 /PRNewswire/ — ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its lead candidate EB8018, a small molecule designed to block...
Saint-Priest, France, October 27, 2017 – Biom’Up, specialist of surgical hemostasis, today provides a regulatory update regarding the United States Food and Drug Administration’s (FDA) review of the company’s Premarket Approval (PMA) application for its HEMOBLASTTM Bellows. The FDA conducted a PMA pre-approval inspection at the Biom’up Saint Priest, France, manufacturing facility. The four-day Premarket...
Press release Biom’Up announces the success of its IPO, raising close to €38.1 million on Euronext Paris First initial public offering in the healthcare sector on the Euronext regulated market in Paris in the last 6 months Strong institutional demand in France as well as abroad, especially in the United States and the United Kingdom:...
BIO Buzz Center with Ciara Kennedy – President & CEO, Amplyx Pharmaceuticals, Inc. at the 2017 BIO Investor Forum in San Francisco.
Lund, Sweden, 08:00 CEST 19 October 2017 – BONESUPPORT™ an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform, will publish its Q3 2017 Interim Report on Thursday 2 November 2017 at 08.00am CEST. The Company will...
1 2 3 37

Lundbeckfonden Ventures

News

BONESUPPORTTM – CERAMENT® G’s POTENTIAL TO PREVENT AND MANAGE BIOFILM-RELATED BONE INFECTIONS HIGHLIGHTED IN NEW HIGH-PROFILE PUBLICATION
14. November 2017
Spero Therapeutics Announces Pricing of Initial Public Offering
3. November 2017
BONESUPPORT HOLDING AB (publ) – Interim Report – January – September 2017
2. November 2017